Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Share Class Description:
FRA:WEK: Ordinary SharesDescription
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.1 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -283.99 | |||||
Beneish M-Score | 389.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -72.4 | |||||
3-Year EPS without NRI Growth Rate | -69.1 | |||||
3-Year FCF Growth Rate | -81.1 | |||||
3-Year Book Growth Rate | -64.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 89.73 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -56.14 | |||||
12-1 Month Momentum % | -22.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.16 | |||||
Quick Ratio | 5.16 | |||||
Cash Ratio | 2.72 | |||||
Days Sales Outstanding | 152.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | 266.79 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -225033.33 | |||||
Net Margin % | -318833.33 | |||||
FCF Margin % | -267850 | |||||
ROE % | -189.69 | |||||
ROA % | -144.17 | |||||
ROIC % | -362.68 | |||||
ROC (Joel Greenblatt) % | -548.96 | |||||
ROCE % | -182.14 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 812.5 | |||||
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.38 | |||||
EV-to-EBIT | 0.04 | |||||
EV-to-EBITDA | 0.05 | |||||
EV-to-Revenue | -143 | |||||
EV-to-FCF | 0.05 | |||||
Price-to-Net-Current-Asset-Value | 1.38 | |||||
Price-to-Net-Cash | 3.36 | |||||
Earnings Yield (Greenblatt) % | 2500.08 | |||||
FCF Yield % | -333.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.006 | ||
EPS (TTM) (€) | 0 | ||
Beta | 0 | ||
Volatility % | 85.66 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0.073571 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | -22.18 | ||
52-Week Range (€) | 1.41 - 4.7 | ||
Shares Outstanding (Mil) | 215.56 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alaunos Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(FRA:WEK)'s stock price today?
The current price of FRA:WEK is €1.41. The 52 week high of FRA:WEK is €4.70 and 52 week low is €1.41.
When is next earnings date of Alaunos Therapeutics Inc(FRA:WEK)?
The next earnings date of Alaunos Therapeutics Inc(FRA:WEK) is 2024-11-14 Est..
Does Alaunos Therapeutics Inc(FRA:WEK) pay dividends? If so, how much?
Alaunos Therapeutics Inc(FRA:WEK) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |